Amgen, Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Amgen, Inc. (AMGN) opened at $187.72 on Thursday. Amgen, Inc. has a one year low of $150.38 and a one year high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05. The firm has a market cap of $136,270.00, a price-to-earnings ratio of 16.96, a PEG ratio of 2.71 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same period in the prior year, the business posted $3.02 earnings per share. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. research analysts predict that Amgen, Inc. will post 12.71 EPS for the current fiscal year.
Amgen declared that its board has authorized a share buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.81%. Amgen’s dividend payout ratio is 41.55%.
AMGN has been the subject of a number of recent research reports. BMO Capital Markets reiterated a “market perform” rating and set a $198.00 price objective on shares of Amgen in a research report on Thursday, October 26th. Mizuho reiterated a “buy” rating and set a $198.00 price objective (up previously from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. BidaskClub upgraded Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $196.00 price objective (up previously from $189.00) on shares of Amgen in a research report on Friday, October 6th. Fifteen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $190.15.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Baker Ellis Asset Management LLC acquired a new position in Amgen during the third quarter worth $108,000. Phocas Financial Corp. acquired a new position in Amgen during the second quarter worth $110,000. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares during the last quarter. Omnia Family Wealth LLC increased its position in Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after buying an additional 147 shares during the last quarter. Finally, Grove Bank & Trust increased its position in Amgen by 87.4% during the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after buying an additional 341 shares during the last quarter. 78.48% of the stock is currently owned by institutional investors and hedge funds.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.